Oppenheimer analyst Hartaj Singh maintained a Buy rating on Moderna (NASDAQ:MRNA) on Sunday, setting a price target of 178,... By Rajesh Kumar Singh and Carl O'Donnell (Reuters) - An advisory ...

Financial giants have made a conspicuous bullish move on Moderna. Our analysis of options history for Moderna (NASDAQ:MRNA) revealed 17 unusual trades. Delving into the details, we found 47% of ...

Moderna recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded their patent ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 3103.07 with a total volume of 1,821.00. In the following chart, we are able to follow the development of ...

Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ETCompany ParticipantsRose Loughlin - EVP of ...

Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN). Moderna (NasdaqGS:MRNA) recently faced significant legal challenges with five international lawsuits from ...

Walgreens jumps as Sycamore agrees to $11.45 a share purchase Sycamore Partners agreed to acquire Walgreens Boots (WBA) in a ...

Leaving Copenhagen’s castle-like station, the train (5.3 hours, from 35 euros) traversed the five-mile bridge connecting ...

March 5, 2025 Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...